Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $22.93, for a total transaction of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Myriad Genetics Stock Up 4.4 %
MYGN stock opened at $24.08 on Friday. Myriad Genetics, Inc. has a twelve month low of $13.82 and a twelve month high of $29.30. The company has a current ratio of 1.96, a quick ratio of 1.78 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $2.18 billion, a P/E ratio of -8.54 and a beta of 1.91. The firm has a 50 day simple moving average of $27.09 and a 200-day simple moving average of $24.52.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. The business had revenue of $211.50 million during the quarter, compared to the consensus estimate of $206.44 million. During the same quarter last year, the company earned ($0.21) earnings per share. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, equities research analysts predict that Myriad Genetics, Inc. will post -0.34 earnings per share for the current fiscal year.
Institutional Trading of Myriad Genetics
Wall Street Analysts Forecast Growth
MYGN has been the subject of a number of research analyst reports. Piper Sandler increased their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 13th. Scotiabank increased their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, August 13th. Morgan Stanley initiated coverage on shares of Myriad Genetics in a research report on Thursday, September 19th. They set an “equal weight” rating and a $32.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 7th. Finally, TD Cowen increased their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.91.
Read Our Latest Stock Analysis on MYGN
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Stories
- Five stocks we like better than Myriad Genetics
- How Can Investors Benefit From After-Hours Trading
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is the S&P 500 and How It is Distinct from Other Indexes
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.